A Phase 1 interventional study of AD-116A and AD-1161 in Benign Prostatic Hyperplasia, sponsored by Addpharma Inc.. Not yet recruiting at 1 site in South Korea. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of — 6 open to participants now, 6 under way, none of them phase 3. Prostatic Hyperplasia · Korea, Republic of.
Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, this one is the 36th largest by planned enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2026, is one of 20 in phase 1, and was the 72nd registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →6 of the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+ · Men only · Healthy volunteers
Saint Vincent's Hospital, Korea · Sites in Korea, Republic of
Ages 50+ · Men only
Société Internationale d'Urologie · Sites in Korea, Republic of, United States, Canada and 18 more countries
Ages 18+ · Men only
AJU Pharm Co., Ltd. · Sites in Korea, Republic of
Ages 19–54 · Men only · Healthy volunteers
Addpharma Inc. · Sites in Korea, Republic of
Ages 19+ · Men only · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 19 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 44 is below the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 57 interventional studies, 300 across the 15 observational. Of the 54 that completed or were terminated, 8 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 72 have an industry lead sponsor. The 10 most frequent:
This study is registered under Addpharma Inc., one of the names counted as Yuhan Corporation. Under that name alone:
Addpharma Inc. is the lead sponsor of 58 studies on the registry; 25 are open to participants now.
Yuhan Corporation has 4 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compares and evaluates the bioequivalence of AD-116A and AD-1161 in healthy adult male volunteers under fed conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1 : Reference Drug(AD-1161), Period 2 : Test Drug(AD-116A)
Drug: AD-116A · Drug: AD-1161
Period 1 : Test Drug(AD-116A), Period 2 : Reference Drug(AD-1161)
Drug: AD-116A · Drug: AD-1161
Oral Capsule
Oral Capsule
1. Area under the plasma concentration-time curve during dosing interval (AUCt)
AUCt of AD-116A
Time frame: [Time Frame: pre-dose (0hour) to 48hours]
2. Maximum concentration of drug in plasma (Cmax)
Cmax of AD-116A
Time frame: [Time Frame: pre-dose (0hour) to 48hours]
Start is estimated for Jul 2026; primary completion for Oct 2026, 3 months later.
Of 26 industry-sponsored phase 1 interventional studies under Prostatic Hyperplasia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 4. This study's planned 3 months is close to that.
Counting every sponsor, half of 34 studies reached it within 3 months; a quarter within 1 and three quarters within 6.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AD-1161